Pharma Industry

Forget Baba’s magic pill. Kaadha to favipiravir, pandemic has given a new meaning to repurposed drugs.


When policies have to be diluted and clinical trial protocols compromised for drugs to get quick approvals, the patients may have to pay a high price for it. However, in the frenzied pursuit of an anti-coronavirus vaccine or medicine, a handful of companies are not giving into the temptation of falling for instant gratification over safety.

As we continue to ‘science the hell’ out of this pandemic, let us match our scientific prowess with humility and a commitment to the patients we pride ourselves on serving. — Vicki L Sato, chairperson of Denali Therapeutics, and VIR Biotechnology, writes in Biotechnology in the time of Covid-19 — Commentaries from the Front Line. Earlier this week, when Patanjali Ayurved rolled out a medicine kit that the company claimed can cure the novel

  • SAVE

Sign in to read the full article

You’ve got this Prime Story as a Free Gift

Already a Member?

Why ?

  • Sharp Insight-rich, Indepth stories across 20+ sectors

  • Access the exclusive Economic Times stories, Editorial and Expert opinion

  • Clean experience with
    Minimal Ads

  • Comment & Engage with ET Prime community

  • Exclusive invites to Virtual Events with Industry Leaders

  • A trusted team of Journalists & Analysts who can best filter signal from noise

Source link